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Abstract 
Objectives: Paclitaxel (PTX) is frequently used in the clinical treatment of solid tumors. But the PTX‑resistance is a 
great obstacle in cancer treatment. Exploration of the mechanisms of drug resistance suggests that tumor suppressor 
genes (TSGs) play a key role in the response of chemotherapeutic drugs. TSGs, a set of genes that are often inacti‑
vated in cancers, can regulate various biological processes. In this study, an overview of the contribution of TSGs to 
PTX resistance and their underlying relationship in cancers are reported by using GeneMANIA, a web‑based tool for 
gene/protein function prediction.
Methods: Using PubMed online database and Google web site, the terms “paclitaxel resistance” or “taxol resistance” 
or “drug resistance” or “chemotherapy resistance”, and “cancer” or “carcinoma”, and “tumor suppressor genes” or “TSGs” 
or “negative regulated protein” or “antioncogenes” were searched and analyzed. GeneMANIA data base was used to 
predict gene/protein interactions and functions.
Results: We identified 22 TSGs involved in PTX resistance, including BRCA1, TP53, PTEN, APC, CDKN1A, CDKN2A, HIN‑1, 
RASSF1, YAP, ING4, PLK2, FBW7, BLU, LZTS1, REST, FADD, PDCD4, TGFBI, ING1, Bax, PinX1 and hEx. The TSGs were found to 
have direct and indirect relationships with each other, and thus they could contribute to PTX resistance as a group. 
The varied expression status and regulation function of the TSGs on cell cycle in different cancers might play an 
important role in PTX resistance.
Conclusion: A further understanding of the roles of tumor suppressor genes in drug resistance is an important step 
to overcome chemotherapy tolerance. Tumor suppressor gene therapy targets the altered genes and signaling path‑
ways and can be a new strategy to reverse chemotherapy resistance.
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Background
Currently, chemotherapy is the main cancer treatment 
modality, among which paclitaxel (PTX) is a type of cyto-
toxic agent and widely used in the first line treatment of 
lung, ovarian, breast, renal cancers and Kaposi’s sarcoma 
[1–5]. PTX differs from conventional anti-cancer drugs 
because it does not affect the DNA or RNA synthesis of 
tumor cells or cause DNA damage, but interferes with 
tubulin to stabilize microtubule composition and normal 
spindle assembly and cell division resulting in cancer cell 
death [6].
The clinical use of PTX leads to variable responses in 
different individuals, and the mechanisms of PTX resist-
ance have not been fully elucidated. Some reports sug-
gested that tumor suppressor genes (TSGs) should be 
important mediators of drug sensitivity [7–9]. Normally, 
these TSGs prevent abnormal cells from surviving. How-
ever, when the genes are inactivated or reduce expres-
sion, the abnormal cells grow uncontrollably, which may 
lead to cancer formation [10].
In this study, by the analysis of published reports and 
GeneMANIA network, we reviewed 21 TSGs and 1 
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putative TSG that contributed to PTX resistance in can-
cer and provided an overview of the relationship of TSGs 
with PTX resistance.
Overall information on the 22 genes related to PTX 
resistance in cancer
To comprehensively collect all of the TSGs related to 
PTX resistance, we searched the PubMed online data-
base and google web site, followed by an advanced search 
using the terms “paclitaxel response” or “paclitaxel sensi-
tive” and “drug resistance” or “chemotherapy resistance,” 
and “cancer” or “carcinoma,” and “tumor suppressor 
genes” or “negative regulated protein” or “antioncogene” 
This search identified 22 TSGs including breast cancer 
1 (BRCA1), tumor protein p53 (TP53), phosphatase and 
tension homolog (PTEN), adenomatous polyposis coli 
(APC), cyclin-dependent kinase inhibitor 1A (CDKN1A), 
cyclin-dependent kinase inhibitor 2A (CDKN2A), high 
in normal-1 (HIN-1), ras association domain-contain-
ing protein 1 (RASSF1), yes-associated protein 1 (YAP), 
inhibitor of growth 4 (ING4), polo-like kinase 2 (PLK2), 
f-box and WD repeat domain containing 7 (FBW7), zinc 
finger MYND type containing 10 (BLU), leucine zipper 
tumor suppressor 1 (LZTS1), re-1 silencing transcrip-
tion factor (REST), fas-associated death domain protein 
(FADD), programmed cell death 4 (PDCD4), transform-
ing growth factor-β-induced (TGFBI), inhibitor of 
growth 1 (ING1), bcl-2-associated X protein (Bax), PIN2/
TRF1 interacting telomerase inhibitor 1 (PinX1) and one 
putative tumor suppressor gene, FERM domain-contain-
ing protein 6 (hEx), which contributed to PTX-resistance 
in cancer. The status, regulation manner, pathway and 
cancer type involved in PTX-resistance have been sum-
marized, as shown in Table 1.
BRCA1
Tumor suppressor BRCA1 is involved in several cellular 
functions including DNA damage repair, cell cycle check-
point activation and transcription [11]. Several preclini-
cal studies indicated that BRCA1 might be an important 
determinant of response to PTX-based chemotherapy. 
It was shown that reconstitution of exogenous BRCA1 
in the BRCA1-mutant HCC1937 breast cancer cell line 
resulted in enhanced sensitivity to PTX [12]. In accord-
ance, low BRCA1 mRNA expression in ovarian cancer 
cell lines resulted in decreased and increased apoptotic 
response to PTX and platinum respectively and PTX-
sensitive human brain and neck squamous cell carcinoma 
(HNSCC) with acquired cisplatin resistance had high 
expression of BRCA1 [13, 14]. In order to investigate the 
underlying PTX-resistance mechanisms conferred by loss 
of BRCA1, Chabalier et al. reduced BRCA1 protein levels 
by using small interfering RNA (siRNA) in MCF7 breast 
cancer cells resulted in PTX resistance through premature 
inactivation of spindle checkpoint [15]. Sung et al. found 
that BRCA1 knockdown conferred A549 cells resistance 
to PTX and sensitivity to cisplatin through improving 
microtubule dynamics which prevented the formation of 
stable microtubule for caspase-8 accumulation of PTX 
induced apoptosis [16]. A further study suggested that 
BRCA1 might represent an important mediator of the 
PTX stress-response dependent c-Jun N-terminal kinase/
stress-activated protein kinase (JNK/SAPK) or p38/
mitogen-activated protein kinase (p38/MAPK) pathway 
[17]. Taken together, these studies provided evidence that 
BRCA1 mutation or reduced expression could predict 
the response to PTX–based chemotherapy. BRCA1 defi-
ciency led to increased microtubule dynamics, impaired 
cell cycle checkpoint and signaling pathway which ren-
dered less sensitivity to PTX-induced apoptosis. Here we 
consider that BRCA1 may become a molecular marker to 
predict the PTX resistance.
TP53
TP53 is one of the earliest detected tumor suppressor 
genes and the most frequently mutated gene in carci-
noma. More than half of the TP53 mutations found in 
cancers lead to loss of function. Functional p53 partici-
pates in various cellular processes including cell cycle 
progression, cell motility, aging, apoptosis, genetic insta-
bility, DNA repair, anti-angiogenesis and cell metabo-
lism [18]. TP53 gene mutation status has recently been 
shown to be correlated to PTX-based therapy and prog-
nosis [19–21]. It was also found that an augmented 
concentration of intracellular p53 protein sensitized 
three non-small-cell lung carcinoma (NSCLC) cell lines 
to PTX [22]. p53 upregulated modulator of apoptosis 
(PUMA) is an important regulator of apoptosis and is 
involved in drug resistance [23]. It was demonstrated 
that PUMA was downregulated in PTX-resistant ovarian 
cell line SKOV3/PTX, and delivery of p53 into SKOV3/
PTX could upregulated the expression of PUMA and 
restored the apoptotic response to PTX [24]. TP53 hot 
spot mutation (TP53-m273) increased multidrug resist-
ance protein 1 (MDR1, regulating efflux of PTX and dox-
orubicin) expression and resistance to PTX [25, 26]. In 
addition, studies suggested that some regulatory factors 
depended on p53 related pathway may mediated PTX 
resistance. For example, the up-regulation of inhibitor of 
apoptosis-stimulating protein of p53 (iASPP), a p53 sup-
pression factor, has been found to affect PTX sensitivity 
in ovarian cancer by inhibiting both mitotic catastro-
phe and apoptosis [27]. Astrin, a protein localized with 
mitotic spindles at M phase, silencing of astrin triggered 
a p53-dependent apoptotic pathway and induced Hela 
cells sensitive to PTX [28].
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PTEN
PTEN, is a negative regulator of the phosphatidylinositol 
3-kinase/protein kinase B (PI3k/Akt) signaling pathway. 
Its dysfunction mutation results in reduced dephos-
phorylation of phosphatidylinositol 3, 4, 5-triphosphate 
(PIP3), further increasing cell survival, cell migration, 
cell size and cell proliferation [29]. Recently, reports 
mainly concentrate on the role of PTEN in the response 
of human cancer cells to anti-cancer drugs and in mul-
tiple drug resistance (MDR) reversion [30–33]. Several 
reports showed that PTEN was involved in PTX resist-
ance. Cyclin B1 plays a key role in G2/M transition. Ou 
et al. detected suppressing of cyclin B1 protein sensitized 
esophageal squamous cell carcinoma (ESCC) cells to 
Table 1 General overview of the 22 TSGs that contribute to PTX-resistance
TSG abbreviation Full name of the TSGs Status Regulation manner Pathway associated 
with resistance
Type of cancer
BRCA1 Breast cancer 1 Mutation [12, 17]












Breast cancer [15, 17]
NSCLC [16]
TP53 Tumor protein p53 Mutation [26] G1 phase arrest [22]
Apoptosis [24]
Apoptosis [24] NSCLC [22]
Ovarian cancer [24, 26]
PTEN Phosphatase and ten‑ 
sion homolog
Protein level [34, 35] Cyclin B1 activity [34]
MiR‑22 [35]




APC Adenomatous polyposis 
coli
Mutation [38] MDR1 [38]
miR‑135a [40]




p21/CDKN1A Cyclin‑dependent  
kinase inhibitor 1A
Protein level [48] Cell cycle [48] Cell cycle, Apoptosis  
[48]
Melanoma [48]
p16/CDKN2A Cyclin‑dependent  
kinase inhibitor 2A
Protein level [49] Cell cycle [49] Cell cycle [49] Triple‑negative breast 
cancer [49]
FRMD6/hEx FERM domain‑contain‑ 
ing protein 6
Protein level [8] Cell cycle [8] Cell cycle [8] Breast cancer [8]
RASSF1 Ras association domain‑
containing protein 1
Methylation [54] Cell growth [53] Cell cycle [53] Ovarian cancer [53]
YAP Yes‑associated protein 1 deletion [55] Cell cycle [55] Cell cycle [55] Breast cancer [55]
ING4 Inhibitor of growth 4 Protein level [56] Bcl‑2/Bax ratio [56] Apoptosis, Cell cycle  
[56]
Lung cancer [51]
BAX BCL2‑associated X  
protein
mRNA level [57] Bcl‑2/Bax ratio [57] Apoptosis [57] Breast cancer [57]
HIN‑1/SCGB3A1 High in normal‑1 Methylation [9] Apoptosis [9] PI3K/AKT pathway [9] Ovarian cancer [9]
PLK2 Polo‑like kinase 2 Methylation [58] G2/M phase checkpoint 
[58]
Cell cycle, apoptosis  
[58]
Ovarian cancer [58]
LZTS1/FEZ1 Leucine zipper tumor 
suppressor 1
Protein/mRNA level  
[59, 60]
Cell cycle [59, 60] Cell cycle [59, 60] Ovarian cancer [59]
Breast cancer [60]
FBXW7/FBW7 F‑box and WD repeat 
domain containing 7
Mutation [62] Ubiquitination [62] Ubiquitination [62] Ovarian cancer [62]
ZMYND10/BLU zinc finger MYND type 
containing 10
Methylation [63] Bcl‑2/Bax ratio [63, 64] Apoptosis [63], PI3 K/ 
Akt pathway [59, 64]
Ovarian cancer [63, 64]
TGFBI Transforming growth 
factor‑β‑induced
mRNA/protein level  
[66, 67]
β3 integrin [66, 67] Apoptosis [66, 67] NSCLC [66]
Ovarian cancer [67]
REST RE‑1 silencing transcrip‑
tion factor
Protein level [70] TUBB3[70] PI3K/AKT pathway [70] Ovarian cancer [70]
FADD Fas‑associated death 
domain protein
Phosphorylation [72, 73] Apoptosis [71]
Cell cycle [72]
JNK/SAPK pathway [72] Cervical carcinoma [71, 
73]
Prostate cancer [72]
PDCD4 Programmed cell  
death 4
Protein/mRNA level  
[74, 75]




ING1 Inhibitor of growth 1 Protein level [76] Apoptosis [76] p53‑dependent path‑ 
way [76]
Osteosarcoma [76]
PinX1 PIN2/TRF1 interacting 
telomerase inhibitor 1
Protein level [77] Spindle‑assembly  
checkpoint [77]
Cell cycle [77] Cervical carcinoma [77]
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PTX-induced apoptosis through the PTEN/PI3  k path-
way [34]. Overexpression of microRNA 22 (miR-22) 
reversed PTX-induced cytotoxicity and this function was 
mediated by the regulation of PTEN levels in TP53 nega-
tive colon cell line [35]. Although PTEN is not the pri-
mary target of PTX resistance, evidences showed that its 
regulator can be an important target, such as suppression 
of cyclin B1, miR-22 or combining with inhibitor of Akt 
could be an attractive strategy for PTX therapy.
APC
Tumor suppressor gene APC is most commonly mutated 
and deleted in colorectal cancers, as well as many other 
epithelial cancers like breast, gastric and lung can-
cer. The best-known function of the APC protein is the 
regulation of the Wnt signaling cascade through down-
regulation of β-catenin can modulate cell cycle progres-
sion, however, APC has many Wnt independent roles, 
such as microtubule dynamic, cytoskeletal organization 
and cell adhesion [36, 37]. Since PTX is to interfere with 
microtubule protein stability, the interaction between 
APC and PTX has been explored. Monica et al. showed 
loss of APC in breast cancer cells from mouse mam-
mary tumor virus promoter-polyoma middle T-antigen 
(MMTV-PyMT) mouse lead to increased expression of 
MDR1 after treatment with cisplatin and PTX [38]. It has 
been demonstrated that APC expression is regulated by 
a microRNA 135a (miR-135a) [39]. So it is not surprising 
that miR-135a is shown to be involved in PTX resistance 
by downregulation of APC [40]. Moreover, Ling et  al. 
found APC-deficient cancer cells defect in mitotic spin-
dle checkpoint and in cell–cell adhesion and were more 
resistant to PTX [41, 42]. Consequently, APC deficiency 
impairs the PTX sensitivity of cancer cells by interfer-
ing with the mitotic spindle checkpoint and decreasing 
apoptosis.
CKIs
Loss of cell cycle control promotes tumorigenesis, key 
regulators of the cell cycle are a family of serine/threo-
nine kinases: cyclin-dependent kinases (CDKs). CDKs 
act at different stages of the cell cycle and are responsi-
ble for the transition from one cell cycle phase to the next 
[43]. Endogenous cyclin-dependent kinase inhibitors 
(CKIs) are negative regulators of CDKs [44]. There are 
two families of CKIs: the INK4 families, consisted of p16, 
p15, p18 and p19 which can inhibit the complex of cyc-
lin dependent kinase 4/6 (CDK4/6) and cyclin complex 
activities. And the CIP/KIP families include p21, p27 and 
p57, regulate border CDKs [45]. Recently, evidences have 
showed CKIs family members involved in PTX resistance 
in human cancers. p21, is required to maintain the G2 
arrest after DNA damage [46], the level of p21 expression 
has been known to play an important role in determin-
ing sensitivity of tumor cells to PTX [47], and a remark-
able induction of p21 in A375P cells after treatment of 
PTX and apoptosis induction after mitotic arrest with 
PTX. However, PTX lightly increased the levels of p21 
in A375P/Mdr cells, which exhibited strong resistance 
to PTX [48]. p16, mainly inhibits CDK4 activity, the loss 
of p16 expression reduced the response of breast can-
cer cells to PTX by conferring cancer stem cell proper-
ties and the tumorsphere formation was not significantly 
enhanced [49], those results indicated that CKIs affect 
PTX efficacy mainly through the cell cycle regulation.
Hippo signaling pathway
The Hippo signaling pathway, which regulates cell pro-
liferation and apoptosis, is a highly conserved signaling 
pathway first discovered in Drosophila cells. It also exists 
in mammals and controls organ size, cell proliferation 
and apoptosis. The main function of Hippo signaling 
pathway is to phosphorylate transcriptional co-activator 
PDZ-binding motif (TAZ) and YAP, preventing them 
from entering the nucleus and promoting gene transcrip-
tion which induces cell proliferation, metastasis and inva-
sion [50]. Recent discoveries have identified the Hippo 
signaling pathway as a new target for cancer chemother-
apy resistance [51]. For example, hEx, one of the Hippo 
upstream signal input factors, a putative tumor suppres-
sor gene, overexpression of hEx dramatically inhibited 
breast cancer cell proliferation and sensitivity to PTX [8]. 
RASSF1A, a member of the RASSF1 family, is a down-
stream regulator of Hippo, there are approximately 50 % 
of ovarian tumors harbor hypermethylation of RASSF1 
[52], investigations shown that overexpression of RASS-
FIA could increase stabilization of microtubules then 
restore PTX sensitivity [53]. YAP, a nuclear effector of 
Hippo, has been shown exist in many pathways except 
in Hippo, it is critical for DNA damage in breast can-
cer cells as well as in certain types of neuronal apoptosis 
[54]. It acted as a tumor suppressor in breast cancer and 
its silencing could induce normal breast epithelia more 
resistance to PTX effect on cell cycle but not apoptosis 
[55].
Other TSGs
In addition to the TSGs mentioned above, abnormity of 
ING4, Bax, HIN-1, PLK2, FBW7, LZTS1, BLU, TGFBI, 
REST, FADD, PDCD4, ING1 and PinX1 have also been 
found to mediate PTX resistance in some experiments. 
The protein level of ING4 was sharply decreased in PTX-
resistance lung cancer cells. In contrast, overexpres-
sion of ING4 protein could induce apoptosis and G2/M 
arrest by decreasing B-cell CLL/lymphoma 2 (Bcl-2)/
Bax ratio then reversed PTX-resistance [56]. Bax is a 
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proapoptotic Bcl-2 family member that plays a key role 
in induction of mitochondrial dependent apoptosis. 
Study found there was an increase of Bcl-2/Bax ratio in 
PTX-resistant breast cancer cell lines, high ratio reduced 
the PTX-induced apoptosis in breast cancer and ovar-
ian cancer cells [57]. Hypermethylation downregulated 
the expression of HIN-1 and weakened the sensitivity to 
PTX through the PI3k/Akt pathway [9]. Hypermethyla-
tion of PLK2 reduced ovarian cancer cells sensitivity to 
PTX, accompanied by reduced G2-M arrest and apopto-
sis [58]. Low protein expression of LZTS1 showed little 
response in patients who received PTX-based chemo-
therapy in ovarian carcinoma and breast cancer patients, 
it was a worse prognosis patients outcome [59, 60], previ-
ous study by generating LZTS1 knockout mice, detected 
accelerate mitotic progression resistance to PTX-induced 
M phase arrest by decreasing CDK1 activity [61], indi-
cated cell cycle distribution may be involved in the above 
two human cancer. Ovarian and colon cancer cells which 
harbored mutant FBW7 were more resistant to PTX, 
functional FBW7 is required to degrade myeloid cell leu-
kemia 1 expression by a ubiquitin ligase SKP1–cullin-1–
F-box complex that contains FBW7 [62]. Ovarian cancer 
patients with methylated BLU had significantly shorter 
progression free survival, in  vitro, BLU could decrease 
the Bcl-2/Bax ratio in ovarian cancer cells when encoun-
tered with PTX [63, 64]. TGFBI acts as a tumor suppres-
sor in lung cancer [65]. Irigoyen et al. identified a strong 
association between elevated TGFBI expression and the 
response to chemotherapy, TGFBI mediated the suscep-
tibility of NSCLC cells to PTX and this may be the result 
of direct TGFBI induction of cell apoptosis through the 
binding of its proteolytic fragments to the β3 integrin, 
the same phenomenon was proven in ovarian cancer [66, 
67]. REST directly regulates Akt2, loss of REST leads to a 
de-regulation of Akt phosphorylation [68]. Tubulin beta 
3 class III (TUBB3) was a biomarker of the resistance 
of chemotherapies [69]. Gao et  al. found REST might 
suppress the expression of TUBB3 to sensitize ovarian 
cancer cells to PTX by activating the PI3k/Akt pathway 
[70]. Phosphorylation of FADD affected both upstream 
and downstream of the JNK/SAPK pathway, which was 
critical for sensitivity to PTX-induced apoptosis [71–73], 
and PDCD4 mediated PTX sensitivity through interact-
ing mitotic exit regulation axis, upregulation of micro-
RNA 182 (miR-182) accelerated cell cycle process and 
enhanced chemo-resistance of ovarian cancer cells to 
PTX through negatively regulating PDCD4 [74, 75]. 
P33ING1, one of the ING1 gene products, could enhance 
PTX-induced apoptosis in human osteosarcoma U2OS 
cells by p53-dependent pathway and its target genes 
p21 and Bax were increased [76]. In cervical squamous 
cell carcinomas, the expression of PinX1 in patients was 
significantly associated with the response of the com-
bination of PTX and cisplatin chemotherapy. In vitro, 
knockdown of PinX1 could dramatically enhance PTX 
effects, whereas the augment of PinX1 levels substantially 
enhanced the G2 phase cells through influencing spindle 
assembly checkpoint [77].
Summarily, the pre-transcriptional (epigenetic/
genetic), transcriptional and post-transcriptional changes 
of TSGs contribute to PTX resistance in cancer, which 
may lead to new treatment methods to overcome drug 
resistance. Actually, the reversion of epigenetic changes 
of DNA and gene transfer skills (gene therapy) has 
already proved to be effective in reversing PTX resist-
ance. For example, 5-aza-2-deoxycytidine (a demethyla-
tion agent) reversed the sensitivity to PTX treatment in 
breast cancer and ovarian cancer cells [9, 78]. Exogenous 
increased levels of p53 significantly improved the sen-
sitivity of PTX providing a basis for gene therapy [22]. 
For another example, the CDK4/6 inhibitor was shown 
to downregulate p16/cyclin D1/CDK4/(retinoblastoma 
protein)Rb signaling pathway and enhance the cytotoxic-
ity of PTX for KRAS mutation-positive lung adenocarci-
noma cells [79]. These results encouraged further studies 
on TSGs associated with PTX resistance in cancers. 
Moreover, drug resistance was rarely induced by single 
gene, it was almost caused by two or more genes. For 
example, tumor suppressor p33ING1 markedly increased 
PTX-induced growth inhibition and apoptosis in TP53-
wild cells, but not in TP53-mutant cells [76]. Twenty two 
genes were involved in the regulation of PTX resistance 
in cancers through certain pathways, particularly through 
cell cycle and apoptosis (Table 1).
The interaction network of the 22 TSGs
Bioinformatics analysis has been widely used in nature 
and life sciences, and it is a feasible and valuable method 
for gene/protein function prediction. Numerous net-
works of molecular interactions have made it possible to 
study gene/protein function using online databases [80]. 
GeneMANIA is a web-based interface for prediction of 
gene/protein function on the basis of multiple networks 
derived from different proteomics and genomic data, and 
it is fast enough to predict gene/protein function with a 
significant accuracy rate [81]. The protein interactions 
of the 22 genes were analyzed using GeneMANIA. The 
co-localization, co-expression, pathway, shared protein 
domains and genetic, physical and predictive interac-
tions of the 22 TSGs were shown in Figs. 1, 2, 3, 4, 5, 6, 
7 (Genes/proteins are depicted as colored circles and 
experimentally detected relationships between genes/pro-
teins as connecting lines. Black circles are the 22 TSGs, 
gray circles are other genes/protein related to the 22 
TSGs). In detail, BRCA1 has similar expression level with 
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CDKN2A, participates in the same pathway with TP53, 
and has physical interactions with CDKN2A and TP53. 
TP53 has similar expression level with FADD, PDCD4, 
Fig. 1 The co‑expression network of the 22 TSGs based on GeneMA‑
NIA. Co‑expression: two genes are linked if their expression levels are 
similar across conditions in a gene expression study
Fig. 2 The co‑localization network of the 22 TSGs based on GeneMA‑
NIA. Co‑localization: two genes are linked if they are both expressed 
in the same tissue or if their gene products are both identified in the 
same cellular location
Fig. 3 The predicted network of the 22 TSGs based on GeneMANIA. 
Predicted: predicted functional relationships between genes, often 
protein interaction
Fig. 4 The genetic interactions network of the 22 TSGs based on 
GeneMANIA. Genetic interaction: Two genes are functionally associ‑
ated if the effects of perturbing one gene were found to be modified 
by perturbations to a second gene
Fig. 5 The pathway network of the 22 TSGs based on GeneMANIA. 
Pathway: Two gene products are linked if they participate in the same 
reaction within a pathway
Fig. 6 The physical interaction network of the 22 TSGs based on 
GeneMANIA. Physical Interaction: two gene products are linked if 
they were found to interact in a protein–protein interaction study
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CDKN1A and Bax, participates in the same pathway with 
BRCA1, APC, CDKN1A, PTEN and Bax, and has physi-
cal interactions with BRCA1, ING1, CDKN1A, ING4, 
Bax and CDKN2A. PTEN has similar expression level 
with PDCD4, FBW7, TP53, PLK2, APC and TGFBI, par-
ticipates in the same pathway with TP53, and has physical 
interactions with TP53, FBW7. APC has co-localization 
with FBW7 and the similar expression level with FBW7, 
hEx, PTEN and REST, and participates in the same path-
way with TP53. CDKN1A has the similar expression level 
with TGFBI, ING1, FADD, TP53, CDKN2A and PLK2, 
and the same protein domain and physical interaction 
with TP53. CDKN2A has the similar expression level with 
CDKN1A, CDKN2A, and physical interactions with ING1, 
BRCA1, TP53, ING4. hEx has the similar expression level 
with FBW7, ING1, RASSF1, PLK2, REST, PDCD4 and 
TGFBI. RASSF1 has the similar expression level with 
BLU, ING4 and TGFBI. YAP has the similar expression 
level with TGFBI, PinX1, ING1, ING4 and FADD. ING4 
has the similar expression level with YAP, RASSF1, FADD, 
PDCD4, Bax and PLK2, the same protein domain with 
ING1 and physical interactions with TP53 and CDKN2A. 
HIN-1 has the similar expression level with FADD, 
REST, LZTS1 and BLU. PLK2 has the same protein loca-
tion with TGFBI, and the similar expression level with 
TGFBI, PTEN, LZTS1, ING4, CDKN1A, ING1, hEx and 
FBW7. LZTS1 has the similar expression level with PLK2, 
FBW7 and HIN-1. FBW7 has the same protein location 
with APC, interacts with REST and PTEN, and has the 
similar expression level with PLK2, APC, TGFBI, LZTS1, 
PDCD4, CDKN1A, PTEN, REST and Bax. BLU has the 
similar expression level with RASSF1, PDCD4, HIN-1 
and REST. TGFBI has the similar expression level with 
FBW7, hEx, Bax, PTEN, CDKN1A, YAP and RASSF1. 
REST has the similar expression with BLU, APC, PinX1, 
FBW7, FADD and HIN-1. FADD has the similar expres-
sion of ING1, PinX1, CDKN1A, ING4, HIN-1, REST, YAP, 
Bax and TP53. PDCD4 has the similar expression with 
FBW7, TP53, ING4, BLU and PTEN. Bax has the simi-
lar expression with ING4, PinX1, TP53, CDKN1A, ING1, 
FBW7, FADD and TGFBI, and participates in the same 
pathway with TP53. PinX1 has the similar expression level 
with YAP, REST, Bax and FADD. ING1 shares the same 
protein domain with ING4 and interacts with TP53 and 
CDKN2A. The cross-interaction of the 22 TSGs demon-
strates that these genes may contribute to PTX resistance 
as a group.
Annotated molecular functions of the 22 TSGs according 
to the protein interaction network
The molecular function of the 22 TSGs may be predicted 
by using GeneMANIA network. By analysis, there were 
four summarized functions to be possibly close to chem-
otherapy resistance (Table 2). The cell cycle-related func-
tion covered 12 of the 22 TSGs and additional 10 genes. 
The cell apoptosis-related function covered eight TSGs 
and additional seven genes. The protein ubiquitination-
related function covered six TSGs and additional five 
genes. The cell growth-related function covered seven 
TSGs and additional four genes. Since the cell cycle-
related function was annotated with the highest false 
discovery rate (FDR), the regulation function of TSGs on 
cell cycle was considered more closely related to chemo-
therapy resistance than other three pathway functions.
Other related genes in the network
In the network, 20 other related genes/proteins that medi-
ate the relationship of the 22 TSGs. They have interactions 
Fig. 7 The shared protein domain network of the 22 TSGs based on 
GeneMANIA. Shared protein domains: Two gene products are linked 
if they have the same protein domain
Table 2 Summarized molecular functions of the 22 TSGs according to the protein interaction network
Related function False discovery rate Number of the 22 TSGs Other genes
Cell cycle 7.14e−12 ~ 4.48e−2 PLK2, FBW7, TP53, PTEN, APC, BRCA1, CDKN1A, 
CDKN2A, ING4, RASSF1, PDCD4, FADD
CUL1, CDK2, CDK4, CDKN1C, CDKN1B, GTPBP4, TP63, 
PHF17, BRMS1, STK4
Apoptosis 1.17e−9 ~ 1.16e−2 APC, REST, CDKN2A, FADD, ING4, TP53, Bax, BRCA1 BRMS1, TP63, FAS, STK4, CDKN1B, BCL2, CUL1
Protein ubiquitination 4.97e−9 ~ 4.39e−2 BRCA1, FBW7, TP53, CDKN2A, RASSF1, PTEN BTRC, CUL1, DAXX, GTPBP4, CDK2
Cell growth 1.29e−8 ~ 4.25e−5 PTEN, ING4, TP53, CDKN1A, CDKN2A, ING1, HIN‑1 CDKN1B, PHF17, BCL‑2, BRMS1
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with the 22 candidate genes, and participate in the simi-
lar biological process which the 22 genes are involved 
(Table  2), which indicates that they may be related to 
PTX or other drug resistance in cancers. Some of them 
had been studied in drug resistance. For example, tumor 
protein 63 (TP63), a TP53 family protein, which expressed 
a variety of isoforms. DeltaNp63alpha belonged to the 
members of the N-terminally truncated (DeltaN) p63 sub-
family, it can trigger anti-apoptotic related pathway result 
to chemo-resistance in hepatocellular carcinoma [82]. 
Ovarian cancer cell line with acquired resistance to car-
boplatin revealed low levels of the gene cyclin-dependent 
kinase inhibitor 1C (CDKN1C), and demethylation agent 
can reverse the silencing of CDKN1C and increased the 
apoptotic response to carboplatin [83]. Bcl-2, is specifi-
cally considered as an important anti-apoptotic protein 
and classified as an oncogene, the expression of Bcl-2 can 
affect PTX induced apoptosis [84]. The Bcl-2/Bax ratio 
has shown a significant increase in PTX-resistance can-
cer cells [56, 57]. Hairy/enhancer-of-split related with 
YRPW motif protein 1 (HEY1), cyclin-dependent kinase 
inhibitor 1B (CDKN1B) and fas cell surface death recep-
tor (Fas) acted as a part of signaling pathways involved in 
drug resistance [85]. Death-associated protein 6 (DAXX) 
has been shown to regulate PTX-sensitivity in tumor [86]. 
CDK4 and CDK2 are not only involved in the formation of 
tumor resistance but also the inhibitors of cyclin-depend-
ent kinase which has been the anti-cancer agent used in 
clinic [87].
Conclusion
It is well known that TSGs play an important role in cell 
cycle, angiogenesis and signal transduction, and cur-
rently TSGs are also considered to participate in the for-
mation of chemo-resistance. In this review, we reported 
an overview of the 22 TSGs associated with PTX resist-
ance in cancer. The status and ways of TSGs to regulate 
PTX resistance in several types of cancer were integrated 
in Table  1. Using GeneMANIA, the interaction analysis 
of TSGs was performed and it was shown that cell cycle 
might be the main manner for the participation of TSGs 
in PTX resistance in human cancers, and the 22 TSGs 
had a direct or indirect relationship with each other and 
could contribute to PTX resistance as a group.
Therefore, profiling the TSGs status of individual 
tumors, such as mRNA levels and protein levels, is criti-
cal in guiding the optimization of personalized medicines 
to better sensitize the individual patient to specific drugs. 
Understanding the mechanistic basis and identification 
of robust biomarkers could also predict optimal use of 
chemotherapy in patients. We anticipate that in the future 
such approaches will benefit clinical development of anti-
cancer therapeutics directly or indirectly targeting TSGs.
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